Literature DB >> 7981908

Tumor cells induced by the v-src oncogene are heterogeneous for expression of markers of mesenchyme differentiation.

J M England1, M J Panella, G C Kopen, T W Wisner, M S Halpern.   

Abstract

The observation that v-src-induced tumors contain tumor cells of differing morphology, notably fibroblastoid or polygonal, raised the question as to whether the tumor cells are also heterogeneous with respect to expression of markers of cellular differentiation. Of the markers tested here, consistent reactivity for tumor tissue was noted only for antibody probes reactive to muscle actin (HHF35, alpha sm-1) or to procollagen type I (SP1. D8); for any given tumor, whether induced by v-src DNA or by Rous sarcoma virus, each of these markers was found only in a subpopulation of tumor cells. The observation of marker heterogeneity in the one v-src DNA-induced tumor examined here that typed as monoclonal suggests that v-src-induced transformation is consonant with a degree of plasticity in the phenotypes of the clonal progeny of a single transformant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981908     DOI: 10.1007/BF00197397

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA.

Authors:  J M England; M J Panella; D L Ewert; M S Halpern
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

2.  The immune status of avian sarcoma virus-infected chickens as a determinant of sarcoma growth pattern and viral antigen expression.

Authors:  M S Halpern; S B McMahon
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

3.  Restricted clonality of visceral sarcomas in avian sarcoma virus-infected chickens.

Authors:  M S Halpern; S B McMahon; F Branco
Journal:  Virology       Date:  1989-03       Impact factor: 3.616

4.  Tumor immunity generated in the course of regression of v-src-induced sarcomas.

Authors:  T W Wisner; J M England; D Y Pan; A W Stoker; M S Halpern
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  HHF35, a muscle-actin-specific monoclonal antibody. I. Immunocytochemical and biochemical characterization.

Authors:  T Tsukada; D Tippens; D Gordon; R Ross; A M Gown
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

6.  Postirradiation malignant fibrous histiocytoma expressing cytokeratin. Implications for the immunodiagnosis of sarcomas.

Authors:  S W Weiss; G L Bratthauer; P A Morris
Journal:  Am J Surg Pathol       Date:  1988-07       Impact factor: 6.394

7.  Characterization of human soft tissue sarcomas in nude mice. Evidence for histogenic properties of malignant fibrous histiocytomas.

Authors:  P J Roholl; D H Rutgers; L H Rademakers; R A De Weger; J R Elbers; J A Van Unnik
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

8.  Tumor induction by direct injection of cloned v-src DNA into chickens.

Authors:  Y K Fung; L B Crittenden; A M Fadly; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

9.  Zeugmatin: a new high molecular weight protein associated with Z lines in adult and early embryonic striated muscle.

Authors:  P A Maher; G F Cox; S J Singer
Journal:  J Cell Biol       Date:  1985-11       Impact factor: 10.539

10.  Immunocytochemical analysis of intermediate filaments in embryonic heart cells with monoclonal antibodies to desmin.

Authors:  S I Danto; D A Fischman
Journal:  J Cell Biol       Date:  1984-06       Impact factor: 10.539

View more
  1 in total

1.  Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.

Authors:  Sebastian Oltean; Brian S Sorg; Todd Albrecht; Vivian I Bonano; Robert M Brazas; Mark W Dewhirst; Mariano A Garcia-Blanco
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.